FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079713841> ?p ?o ?g. }

• W2079713841 endingPage "1826" @default.
• W2079713841 startingPage "1819" @default.
• W2079713841 abstract "To determine whether different doses and dosing regimens of intravitreal vascular endothelial growth factor (VEGF) Trap-Eye are superior to focal/grid photocoagulation in eyes with diabetic macular edema (DME).Multicenter, randomized, double-masked, phase 2 clinical trial.A total of 221 diabetic patients with clinically significant macular edema involving the central macula.Patients were assigned to 1 of 5 treatment regimens: 0.5 mg VEGF Trap-Eye every 4 weeks; 2 mg VEGF Trap-Eye every 4 weeks; 2 mg VEGF Trap-Eye for 3 initial monthly doses and then every 8 weeks; 2 mg VEGF Trap-Eye for 3 initial monthly doses and then on an as-needed (PRN) basis; or macular laser photocoagulation. Assessments were completed at baseline and every 4 weeks thereafter.Mean change in visual acuity and central retinal thickness (CRT) at 24 weeks.Patients in the 4 VEGF Trap-Eye groups experienced mean visual acuity benefits ranging from +8.5 to +11.4 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters versus only +2.5 letters in the laser group (P ≤ 0.0085 for each VEGF Trap-Eye group vs. laser). Gains from baseline of 0+, 10+, and 15+ letters were seen in up to 93%, 64%, and 34% of VEGF Trap-Eye groups versus up to 68%, 32%, and 21% in the laser group, respectively. Mean reductions in CRT in the 4 VEGF Trap-Eye groups ranged from -127.3 to -194.5 μm compared with only -67.9 μm in the laser group (P = 0.0066 for each VEGF Trap-Eye group vs. laser). VEGF Trap-Eye was generally well tolerated. Ocular adverse events in patients treated with VEGF Trap-Eye were generally consistent with those seen with other intravitreal anti-VEGF agents.Intravitreal VEGF Trap-Eye produced a statistically significant and clinically relevant improvement in visual acuity when compared with macular laser photocoagulation in patients with DME." @default.
• W2079713841 created "2016-06-24" @default.
• W2079713841 creator A5001966210 @default.
• W2079713841 creator A5002669383 @default.
• W2079713841 creator A5013681612 @default.
• W2079713841 creator A5032106074 @default.
• W2079713841 creator A5035700046 @default.
• W2079713841 creator A5053563726 @default.
• W2079713841 creator A5061673504 @default.
• W2079713841 creator A5072551893 @default.
• W2079713841 creator A5076431250 @default.
• W2079713841 creator A5080631815 @default.
• W2079713841 creator A5083834076 @default.
• W2079713841 creator A5087360949 @default.
• W2079713841 creator A5090191433 @default.
• W2079713841 date "2011-09-01" @default.
• W2079713841 modified "2023-10-14" @default.
• W2079713841 title "The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema" @default.
• W2079713841 cites W1496977463 @default.
• W2079713841 cites W1965477847 @default.
• W2079713841 cites W1979149433 @default.
• W2079713841 cites W1980725734 @default.
• W2079713841 cites W1983943345 @default.
• W2079713841 cites W2004643661 @default.
• W2079713841 cites W2022886290 @default.
• W2079713841 cites W2031484324 @default.
• W2079713841 cites W2036712095 @default.
• W2079713841 cites W2057983131 @default.
• W2079713841 cites W2060308011 @default.
• W2079713841 cites W2091407629 @default.
• W2079713841 cites W2115012618 @default.
• W2079713841 cites W2121919167 @default.
• W2079713841 cites W2128535483 @default.
• W2079713841 cites W2143094951 @default.
• W2079713841 cites W2154711032 @default.
• W2079713841 cites W2324588265 @default.
• W2079713841 cites W2767261857 @default.
• W2079713841 cites W280258025 @default.
• W2079713841 cites W2805868637 @default.
• W2079713841 cites W4233230329 @default.
• W2079713841 doi "https://doi.org/10.1016/j.ophtha.2011.02.018" @default.
• W2079713841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21546089" @default.
• W2079713841 hasPublicationYear "2011" @default.
• W2079713841 type Work @default.
• W2079713841 sameAs 2079713841 @default.
• W2079713841 citedByCount "225" @default.
• W2079713841 countsByYear W20797138412012 @default.
• W2079713841 countsByYear W20797138412013 @default.
• W2079713841 countsByYear W20797138412014 @default.
• W2079713841 countsByYear W20797138412015 @default.
• W2079713841 countsByYear W20797138412016 @default.
• W2079713841 countsByYear W20797138412017 @default.
• W2079713841 countsByYear W20797138412018 @default.
• W2079713841 countsByYear W20797138412019 @default.
• W2079713841 countsByYear W20797138412020 @default.
• W2079713841 countsByYear W20797138412021 @default.
• W2079713841 countsByYear W20797138412022 @default.
• W2079713841 countsByYear W20797138412023 @default.
• W2079713841 crossrefType "journal-article" @default.
• W2079713841 hasAuthorship W2079713841A5001966210 @default.
• W2079713841 hasAuthorship W2079713841A5002669383 @default.
• W2079713841 hasAuthorship W2079713841A5013681612 @default.
• W2079713841 hasAuthorship W2079713841A5032106074 @default.
• W2079713841 hasAuthorship W2079713841A5035700046 @default.
• W2079713841 hasAuthorship W2079713841A5053563726 @default.
• W2079713841 hasAuthorship W2079713841A5061673504 @default.
• W2079713841 hasAuthorship W2079713841A5072551893 @default.
• W2079713841 hasAuthorship W2079713841A5076431250 @default.
• W2079713841 hasAuthorship W2079713841A5080631815 @default.
• W2079713841 hasAuthorship W2079713841A5083834076 @default.
• W2079713841 hasAuthorship W2079713841A5087360949 @default.
• W2079713841 hasAuthorship W2079713841A5090191433 @default.
• W2079713841 hasConcept C118487528 @default.
• W2079713841 hasConcept C134018914 @default.
• W2079713841 hasConcept C141071460 @default.
• W2079713841 hasConcept C2778257484 @default.
• W2079713841 hasConcept C2779829184 @default.
• W2079713841 hasConcept C2780347916 @default.
• W2079713841 hasConcept C2780827179 @default.
• W2079713841 hasConcept C2780886150 @default.
• W2079713841 hasConcept C555293320 @default.
• W2079713841 hasConcept C71924100 @default.
• W2079713841 hasConceptScore W2079713841C118487528 @default.
• W2079713841 hasConceptScore W2079713841C134018914 @default.
• W2079713841 hasConceptScore W2079713841C141071460 @default.
• W2079713841 hasConceptScore W2079713841C2778257484 @default.
• W2079713841 hasConceptScore W2079713841C2779829184 @default.
• W2079713841 hasConceptScore W2079713841C2780347916 @default.
• W2079713841 hasConceptScore W2079713841C2780827179 @default.
• W2079713841 hasConceptScore W2079713841C2780886150 @default.
• W2079713841 hasConceptScore W2079713841C555293320 @default.
• W2079713841 hasConceptScore W2079713841C71924100 @default.
• W2079713841 hasIssue "9" @default.
• W2079713841 hasLocation W20797138411 @default.
• W2079713841 hasLocation W20797138412 @default.
• W2079713841 hasOpenAccess W2079713841 @default.
• W2079713841 hasPrimaryLocation W20797138411 @default.
• W2079713841 hasRelatedWork W1973952171 @default.

• next